Tenosynovial giant cell tumor
Jump to navigation Jump to search
|Elizabeth J. Davis, MD|
Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
All lines of therapy
|back to top|
|Study||Years of enrollment||Evidence||Comparator||Comparative Efficacy|
|Tap et al. 2019 (ENLIVEN)||2015-2016||Phase 3 (E-RT-esc)||Placebo1||Superior ORR|
1Patents assigned to placebo were offered open-label pexidartinib after week 24.
- Pexidartinib (Turalio) as follows:
- Cycle 1: 400 mg PO every morning and 600 mg PO every evening
- Cycle 2 onwards: 400 mg PO twice per day
- ENLIVEN: Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, Alcindor T, Ganjoo K, Martín-Broto J, Ryan CW, Thomas DM, Peterfy C, Healey JH, van de Sande M, Gelhorn HL, Shuster DE, Wang Q, Yver A, Hsu HH, Lin PS, Tong-Starksen S, Stacchiotti S, Wagner AJ; ENLIVEN investigators. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019 Aug 10;394(10197):478-487. Epub 2019 Jun 19. link to original article link to PMC article contains verified protocol PubMed NCT02371369